NOXXON Presents Final Clinical Data From Phase 1/2 NOX-A12 / Keytruda® Combination Trial in Colorectal and Pancreatic Cancer at the ESMO Virtual Congress 2020

Credit: Business Wire- Published 1 week ago
BERLIN--(BUSINESS WIRE)--Regulatory News: NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), presents today a poster with the final clinical results from the Phase 1/2 study with CXCL12 inhibitor, NOX-A12, and pembrolizumab in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer at the European Society for Medical Oncology (ESMO) Virtual Congress 2020. The enh

You are here

You might like